Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates

We described herein the molecular design of novel in vivo anti-inflammatory 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives (1) planned by applying the molecular hybridization approach. This work also points out to the discovery of LASSBio-930 (1c) as a novel anti-inflammatory and anti-hyperalgesic prototype, which was able to reduce carrageenan-induced rat paw edema with an ED50 of 97.8 μmol/kg, acting mainly as a non-selective COX inhibitor.

We describe herein the discovery of NAH-derivative LASSBio-930 (1c) as a novel in vivo anti-inflammatory and anti-hyperalgesic prototype, that acts as non-selective COX inhibitor.Figure optionsDownload as PowerPoint slide